Trial Profile
Phase I trial of ALD1613 in patients with Cushing's disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs ALD 1613 (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Lundbeck Seattle BioPharmaceuticals Inc.
- 12 Mar 2015 New trial record